Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek

Food and Healthcare Press Releases Wednesday December 20, 2017 08:20
SINGAPORE--20 Dec--PRNewswire/InfoQuest
  • Proceeds to be used to further develop Tessa's advanced solid tumor immunotherapy pipeline
  • Funding round reinforces Tessa's position as an emerging leader in cellular immunotherapy with the vision of bringing transformational change to cancer therapy

Tessa Therapeutics , an international clinical stage biopharmaceutical company focusing on T cell therapy for solid tumors, today announced the completion of a USD 80 million financing round led by Temasek, an investment company headquartered in Singapore, and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.

Andrew Khoo, co-founder and CEO of Tessa Therapeutics, commented: "We are very pleased with the success in this financing round which validates our work and continued progress in the development of Tessa's Virus Specific T cell platform technology and clinical pipeline. Tessa plans to expand its global presence and advance next generation cellular therapies targeting a wide range of cancer indications."

Tessa will use the proceeds from this funding round to further advance its clinical pipeline and to bring new therapies, based on the company's Virus Specific T cell (VST) platform, into clinical trials.

Tessa's VST technology is showing compelling results in the treatment of solid tumors. The company is currently conducting a multi-center Phase III trial targeting nasopharyngeal cancer and a Phase I trial targeting cervical cancer and oropharyngeal cancer.   In recent years, Tessa has built robust operational and supply chain capabilities allowing the company to effectively deliver autologous T cell therapy treatments to a large patient pool internationally.

Virus-Specific T cells are produced through a selective expansion process that gives them the ability to infiltrate and survive in solid tumors long enough to attack and destroy them from within, a key differentiator to other cell therapies. Tessa's VSTs migrate to the tumor site and kill cancer cells with precision leaving healthy cells unharmed, leading to high treatment efficacy and safety.

Contacts
Media:
Tessa Therapeutics
Brunswick Group
Will Carnwath, Ben Fry
TessaTherapeutics@brunswickgroup.com
+65-6426-8188
Investor Relations:
Tessa Therapeutics
Trout Group
Pete Rahmer
prahmer@troutgroup.com
+1-646-378-2973
About Tessa Therapeutics

Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body's potent anti-viral immune response to recognize and kill cancer cells. Tessa's core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa's lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world's largest Phase III T cell immunotherapy trial for any cancer indication. The company has built up robust operational and supply chain capabilities to successfully deliver autologous T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled the company to create a fully-integrated approach to the treatment of cancer with immunotherapy.

For more information on Tessa, please visit www.tessatherapeutics.com
About Temasek

Incorporated in 1974, Temasek is an investment company headquartered in Singapore. Supported by 10 offices internationally, Temasek owns a S$275 billion (US$197b) portfolio as at 31 March 2017, mainly in Singapore and the rest of Asia.

Our portfolio covers a broad spectrum of industries: financial services; telecommunications, media & technology; transportation & industrials; consumer & real estate; life sciences & agribusiness; as well as energy & resources. Our investment activities are guided by four investment themes and the long-term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions.

For more information on Temasek, please visit www.temasek.com.sg

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics